Lataa...
Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies
This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.
Tallennettuna:
| Julkaisussa: | JAMA Intern Med |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5820701/ https://ncbi.nlm.nih.gov/pubmed/28892541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2017.2788 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|